SOONSIXThe short version
Sonova Holding AG
Sonova is the world's largest hearing-care company — Phonak and Unitron hearing aids, Advanced Bionics cochlear implants, and its own AudioNova clinics — a high-margin Swiss medtech whose reported earnings a strong franc keeps masking.
From a January high near CHF 221, the shares slid to a CHF 168 low on the 23 March strategy-day divestment shock, then retraced to about CHF 209 by late July.
CHF 209
Share price
CHF 12.5B
Market cap
CHF 3.6B
FY2026 sales
22.5%
Norm. EBITA margin
SwipeScroll▾
The statements
Reported francs look worse than the business actually ran
FY2021 → FY2026as reported · CHF
RevenueCHF3.6B−7%
Operating margin18.7%+0.8pp
Net incomeCHF439M−20%
EPSCHF7.22−20%
Free cash flowCHF656M+0%
Open the full statements →- Clean signature. A ~74% gross margin, a normalized operating margin above 20%, and cash conversion near 90% — a vertically integrated maker and retailer of hearing aids and cochlear implants.
- An FX-and-divestment optical. FY2026 sales fell 0.2% in francs yet rose 5.9% in local currency; a CHF 221m currency headwind and the Consumer Hearing exit mask the underlying growth.
- Balance sheet as optionality. Net debt/EBITDA of 1.1x and falling, a record CHF 4.70 dividend, and a completed CHF 1.5bn buyback — capital return without strain.
The core tension
The franc has bent reported EPS down for three straight years
Reported diluted EPS (CHF)
Diluted EPS, fiscal years to 31 March — peaked at CHF 10.72 in FY2023, then gave back three years.
- Up 16%, and flat. In FY2026 normalized continuing EPS rose 16.0% in local currency but landed flat in Swiss francs at CHF 10.42 — the strong franc erases the growth before it reaches the bottom line.
- The number the market capitalizes. All-in reported EPS fell to CHF 7.22, dragged by a CHF 106.5m loss on the Consumer Hearing divestment on top of the currency.
- The whole debate. Bulls call the decline an FX illusion that reverses; bears note management guides a further 3–4 point franc drag into FY2027 — a variable neither side controls.
Underneath the franc
Strip out the currency and the engine is taking share
+5.9%
Group sales, local ccy
+9.5%
Wholesale devices, LC
+9.1%
US sales, LC
−11.1%
Cochlear Implants, LC
- Best launch in company history. The Phonak Infinio / Sphere platform, built on a proprietary AI chip, sold over 1.5 million units in year one and pushed US Veterans Affairs share to a five-year high.
- Wholesale is accelerating. The high-margin device arm grew 9.5% in local currency to CHF 1,861.8m and reached double digits in the second half — genuine share gains, not price or FX.
- One sore spot. Cochlear Implants fell 11.1% in local currency, hit by China's volume-based procurement reform and an ageing sound processor.
Quality
The best margins and returns in hearing care
Operating (EBIT) margin — latest fiscal year
Reported operating margin, latest fiscal year; peers in their own reporting currency.
- Peer-leading economics. Sonova out-earns Demant, Amplifon and Cochlear on operating margin, and pairs it with ~19% ROCE and the lowest leverage in the group at 1.1x net debt/EBITDA.
- Technology, not just stores. Amplifon owns more clinics yet earns single-digit margins — the premium economics come from designing the IP-rich device, which Sonova does in-house.
- Closest rival is stretched. Demant grew just 2% organically and has levered to 3.4x net debt/EBITDA after a large retail acquisition.
Where money comes from
One engine carries the company; a small unit drags
Where the CHF 3.6bn comes from — FY2025/26
| Business | FY26 sales (CHF m) | Local-ccy growth |
|---|---|---|
| Wholesale — Phonak, Unitron | 1,862 | +9.5% |
| Retail — 811 AudioNova clinics | 1,492 | mid-single digit |
| Cochlear Implants — Advanced Bionics | 252 | −11.1% |
FY2025/26 continuing operations. Hearing Instruments (Wholesale + Retail) is ~93% of sales.
- You underwrite Hearing Instruments. Wholesale plus Retail is 93% of sales at a 23.7% segment margin; the Cochlear Implants turnaround comes as a near-free option.
- Retail is the steadier half. 811 owned AudioNova clinics fit and sell devices directly — lower margin, grown by bolt-on acquisitions of local chains.
Cash & leverage
Cash-generative and lightly levered — with one asterisk
CHF 519M
Operating free cash flow−10.8% y/y
~90%
Cash conversion, 5-yr
1.1x
Net debt / EBITDA
19.0%
Return on capital
- Fat, reliable cash. Operating cash flow consistently exceeds net income and capex runs under 4% of sales, for roughly 90% cash conversion across the FY2021–25 cycle.
- The asterisk. FY2026 operating free cash flow fell 10.8% and net working capital built to CHF 250.4m from CHF 115.0m as a supplier-payment stretch reversed — the free-cash-flow yield is only ~3.8%.
Net debt CHF 994m at 1.1x EBITDA — inside the company's 1.0–1.5x target range.
Returns over time
Margins dipped from the FY2021 peak; returns are climbing back
Reported EBIT margin and ROCE (%)
Reported EBIT margin and return on capital employed, fiscal years to 31 March.
- Structurally high, cyclically pressured. The reported EBIT margin eased from a FY2021 peak on FX, a heavier Retail mix and one-off charges — not any loss of pricing power.
- ROCE is rising. Return on capital reached 19.0% in FY2026, near the top of the 18–20% band management cites as its through-cycle track record.
The market
Most people who need a hearing aid still go without one
Hearing-aid adoption by severity of loss (%)
Adoption rate by severity of loss, developed vs emerging markets.
- A structural-growth market. Even in rich markets only about two-thirds of severe-loss sufferers wear a device, and under 20% of all who would benefit are treated. Manufacturers model 4–6% annual value growth.
- Cyclical, not a utility. A hearing aid is a big-ticket, often out-of-pocket purchase, so demand tracks confidence — Sonova guides just 2–4% market growth in the year ahead, recovering toward trend.
How the Street sits
A cautious, sell-tilting consensus — but no crowded short
Sell-side ratings — 28 analysts
Rating distribution across 28 analysts; the mean target sits above the CHF 209 price.
- Priced for a flat year. Consensus FY2027 EPS of ~CHF 10.4 is barely above FY2026's normalized CHF 10.42 — the Street is effectively modelling another flat reported year.
- Under-positioned, not bearish. Twelve of 28 analysts sit at sell, yet the mean target is above spot — caution on momentum, with no short base to squeeze and no forced-cover fuel.
The strategy
A new CEO's CHF 6 billion revenue ambition by FY2030/31
Revenue: today vs the FY2030/31 ambition
FY2026 sales
CHF 3.6B
FY2030/31 ambition
CHF 6.0B
Implied 5–10% local-currency sales CAGR from ~CHF 3.6bn today.
- Refocused on hearing care. After exiting Consumer Hearing, the March 2026 strategy targets CHF 6bn of revenue and 7–12% local-currency core-EBIT growth by FY2030/31.
- The Street is sceptical. Analysts call the target ambitious and doubt it is reachable without transformational M&A — which would re-open capital-allocation risk. It sits in no consensus model.
The year ahead
What resolves the debate — and when
Near-term catalysts, ranked by decision value
| When | Event | What it tests |
|---|---|---|
| 12 Nov 2026 | H1 FY2026/27 results | Reported franc EPS finally growing; Wholesale pace holding |
| By Mar 2027 | Consumer Hearing sale terms | New team's capital-allocation credibility; buyback fuel |
| H2 FY2026/27 | New cochlear sound processor | Whether the −11.1% implant slide stabilizes |
| FY2026/27 | Buyback resumption | The un-fired per-share lever, paused since April 2025 |
The 12 November half-year is the only confirmed hard date inside six months.
- One clean print decides the multiple. A reported-EPS beat with Wholesale momentum intact is the trigger the whole thesis waits on — and the reaction is skewed up into a cautious book.
- The tripwire. If Wholesale local-currency growth fades toward low single digits as the Infinio cycle ages, reported EPS stalls a fourth year and the case unwinds.
Valuation
A de-rated compounder at ~20x — priced fairly, not cheaply
Share-price scenarios (CHF)
Bear case
CHF 165
Today
CHF 209
Bull case
CHF 265
12–18 month scenarios around the CHF 209 price.
- Re-rated down, not broken. At ~CHF 209 Sonova trades near 20x forward earnings and ~15x EV/EBITDA — a material de-rating from the 30x-plus it commanded above CHF 380 at the FY2021–22 peak.
- The swing factor is the franc. Bulls see CHF 265 as reported EPS re-couples with ~16% local-currency growth; bears see CHF 165 if the franc keeps grinding and implants stay impaired.
- Paid on cash, it is fair. A ~3.8% free-cash-flow yield and 2.2% dividend for a ~19% ROCE franchise is a fair price for a de-risked compounder — the verdict leans long, awaiting confirmation.
What to watch
A compounding franchise de-rated to ~20x — but the re-rating waits on a franc no one here controls
- 01Wholesale local-currency growth holding high-single/double digits into the 12 November print — a slide toward low single digits as the Infinio cycle ages breaks the share-gain thesis.
- 02Reported Swiss-franc EPS finally growing year-on-year, not just in local currency — a fourth straight down year keeps the multiple capped.
- 03Hearing Instruments normalized EBITA margin holding its ~20% through-cycle floor — a break below is the real thesis-breaker.
- 04Cochlear Implants stabilizing on the H2 processor launch as China procurement pressure annualizes.
This distills the full report tab by tab — the statements, moat, catalysts and valuation behind each screen.
Compiled from the full report · 2026-07-23 · For information, not investment advice.